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Abstract
Purpose The expression of the neutrophil high-affinity
Fc-gamma receptor (CD64) can be used as a diagnostic
marker for bacterial infection and sepsis. The aims of this
study were to determine the diagnostic accuracy of CD64
compared to C-reactive protein (CRP) and white blood cell
count (WBC) in patients hospitalized with acute exacer-
bations of COPD (AECOPD) and to investigate the kinetics
of CD64 expression.
Methods The present study is a prospective, single-centre
observation study. Blood samples were collected from
patients hospitalized with AECOPD at admission and after
6, 24 and 48 h. Retrospective reviews on the patients’
medical records were performed blinded to the CD64
results. The CD64 was measured using the Leuko64 kit
from Trillium Diagnostics, LLC (Maine, USA) with the
CELL-DYN Sapphire Haematology System (Abbott Lab-
oratories, Illinois, USA). Diagnostic accuracy of the CD64,
CRP and WBC was compared using a receiver operating
characteristic (ROC) curve analysis.
Results A total of 113 patients were included. Thirty-six
patients (32 %) had pulmonary infiltrate on chest X-ray at
admission (PI). The CD64 was higher in samples from
patients with AECOPD and PI than those without PI at
admission (median 1.25 vs. 0.60, p = 0.002) and during
48 h of follow-up. The area under the ROC curve of CD64,
CRP and WBC was 0.69, 0.73 and 0.64, respectively,
(p = 0.42 for the test of difference).
Conclusion Neutrophil CD64 expression has about the
same diagnostic accuracy as CRP in diagnosing pneumonia
in patients hospitalized with AECOPD, but does not add to
the diagnostic accuracy of CRP and WBC count.
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Abbreviations
CD64 Neutrophil high-affinity Fc-gamma
receptor expression
COPD Chronic obstructive pulmonary disease
AECOPD Acute exacerbations of COPD
CRP C-reactive protein
WBC White blood cell
PI Pulmonary infiltrate on chest X-ray at
admission
p-AECOPD AECOPD with PI
np-AECOPD AECOPD without PI
ROC Receiver operating characteristic
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FEV1 Forced expired volume (litres) in one
second
FEV1% FEV1 percent of predicted value
FVC Forced vital capacity (litres)
FVC% FVC percent of predicted value
FEV1/FVC FEV1 expressed as a proportion of FVC
ICS Inhaled corticosteroids
LABA Long-acting beta-adrenoceptor agonist
Introduction
Chronic obstructive pulmonary disease (COPD) is char-
acterized by a persistent airflow limitation that is usually
progressive and associated with an enhanced chronic
inflammatory response in the airways and the lungs to
noxious particles or gases. COPD is a leading cause of
morbidity and mortality worldwide, and represent an eco-
nomic and social burden that is both substantial and
increasing [1].
Exacerbations of COPD (AECOPD), episodes of an
acute increase in respiratory symptoms, are associated with
increased airway and systemic inflammation [2, 3].
AECOPD are associated with significant morbidity and an
impaired quality of life, and are the primary drivers of
hospital admissions [4, 5].
About half of the AECOPD are triggered by bacterial
and viral infections, but pollution can also contribute to the
beginning of an exacerbation [6–9]. AECOPD are hetero-
geneous events, and there are no specific biomarkers to
determine their causation [10].
Physicians’ decisions would be more precise if they
could be guided by the results of accurate biomarkers,
which might not only differentiate stable diseases from
exacerbations, but also predict the severity of such events
[11]. After the first publications from Davis and colleagues
in 1995, about the diagnostic potential of neutrophil CD64
[12] and from Bakke and colleagues, who for the first time
reported statistical measures for the performance of CD64
as a diagnostic test in 2001 [13], a number of publications
in the field have shown that the neutrophil CD64 expres-
sion (CD64) could be a useful diagnostic cell-based
parameter of systemic bacterial infection particularly in
relation to sepsis [14–19]. The test performed well in dis-
tinguishing infection from flare-ups in autoimmune disease
[20–22], illustrating usefulness in the early detection of
bacterial infection after surgery [23]. However, in patients
with proven or suspected viral infection, neutrophil CD64
was also increased, though this increase was significantly
lower than in patients with proven bacterial infections [24–
26]. In spite of the substantial research in recent years,
there is no general view on the usability of neutrophil
CD64 in clinical infection diagnostics [27–29]. Specifi-
cally, the diagnostic accuracy of CD64 in patients with
AECOPD has not yet been studied.
The primary aim of this study was to determine the
diagnostic accuracy of CD64 compared to the C-reactive
protein (CRP) and white blood cell (WBC) count in iden-
tifying patients with pneumonia among hospitalized
patients with AECOPD. Secondarily, we wanted to inves-
tigate the kinetics of CD64 expression during the first 48 h
after admissions for AECOPD.
Methods
Study Design
The present study is a prospective, single-centre observa-
tion study.
Participants
Participants were prospectively recruited among patients
hospitalized at the Department of ThoracicMedicine (DTM)
of Trondheim University Hospital (TUH). The initial
investigation of the patients was performed in the emergency
department, and they were invited to participate in the study
if the following criteria were met: (1) a clinical diagnosis of
AECOPD; (2) an established diagnosis of COPD confirmed
by spirometry results in the patients’ medical charts; (3) the
ability to give informed consent. The exclusion criteria were
(1) a malignant disease; (2) bronchiectasis; (3) chronic
bacterial colonization of the airways with Pseudomonas
aeruginosa; (4) long-term immunosuppressive treatment;
(5) long-term antibiotics treatment.
Patients admitted repeatedly were only included at their
first admission. Pneumonia was defined as a new pulmonary
infiltrate on chest X-ray at admission (PI). Patients who had
not undergone chest X-ray at admission were not included
in the analysis. Based on the findings of chest X-ray at
admission, the patients were characterized into two groups:
patients with evidence of AECOPD and PI (p-AECOPD)
and those who had evidence of AECOPD without PI (np-
AECOPD). When the authors retrospectively reviewed the
patients’ medical charts, they were blinded to the CD64
results. The medical charts were reviewed for length of
illness, symptoms, treatment with antibiotic or steroids
within 48 h before admission and during the stay at the
DTM, clinical parameters of the patients, CRP, WBC val-
ues and microbiological results as well as information about
regular medication, unhealthy habits and pulmonary func-
tion results in a stable phase of COPD.
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Informed Consent
Informed consent was obtained from all participants
included in the study.
Sample Collection
CRP and WBC counts were routinely analysed for all
patients in the study, while additional blood samples
(EDTA blood) for CD64 analysis were obtained at
admission and 6, 24 and 48 h after admission. The standard
hospital procedures for microbiological surveys were fol-
lowed at blood sample collection and during the processing
of biological materials (blood cultures and sputum).
Laboratory Measurements
CD64 expression was measured using the Leuko64 kit
from Trillium Diagnostics, LLC (Maine, USA) with the
CELL-DYN Sapphire Hematology System (Abbott Labo-
ratories, Illinois, USA) and Leuko64TM QuantiCALC
software from Trillium Diagnostics, LLC. The software
calculated a CD64 index (CD64), which is supposed to be
less than 1.00 in healthy individuals. Between-day coeffi-
cient of variation was 4.6 % at a level of 2.61.
WBC was measured on Sysmex XE-2100 (Sysmex,
Kobe, Japan). The reference limits in adults were
3.7–10.0 9 109/L, whereas the between-day coefficient of
variation was 2.3 % at 6.7 9 109/L.
CRP was measured using a Roche modular P system
(Roche Diagnostics GmbH, Mannheim, Germany), with
reagents from the manufacturer and from Diagnostic Sys-
tems GmbH, Holzheim, Germany. The reference limit was
less than 5.0 mg/L, and the between-day coefficient of
variation was 6.3 % at 19 mg/L.
All analyses were monitored using the appropriate
internal and external (WBC and CRP) quality control
systems.
All pulmonary function tests (spirometry) were per-
formed using a MasterScreen PFT powered by Sen-
trySuiteTM from Jaeger (Erich Jaeger GmbH, Wu¨rzburg,
Germany), and COPD was defined as a post-bronchodilator
FEV1/FVC\ 0.7 according to the GOLD (2015) criteria.
The physicians who were in charge of the patients were
responsible for the diagnostic procedures, laboratory anal-
yses and all decisions regarding treatment and follow-up.
Statistical Analysis
The distribution of the continuous variables was studied
using Q–Q plots, histograms, values of skewness and
kurtosis, and normality was tested by the Kolmogorov–
Smirnov test. The median value (interquartile range) was
used to present non-normal distributed variables. The
Mann–Whitney U test and Fishers exact test were used to
compare quantitative and categorical data, respectively, in
two groups. The Spearman rank correlation coefficient was
used to study correlations. The Friedman test was used to
examine differences between measurements repeated at
several time points, while receiver operating characteristic
(ROC) curve analysis was used to study the accuracy of the
various diagnostic tests and logistic regression to find the
best combination of diagnostic tests. P values\ 0.05 were
considered to be statistically significant. Statistical analyses
were carried out through the use of computer IBM software
SPSS 21 (Chicago, IL, USA) and StataCorp. 2011. Stata
statistical software: Release 12. College Station, TX: Sta-
taCorp LP.
Results
From May 2011 to May 2013, a total of 159 patients were
invited to participate in the study, with 113 patients
meeting the inclusion criteria. A total of 36 (32 %) patients
were classified as belonging to the p-AECOPD group,
while 77 patients belonged to the np-AECOPD group.
There were no significant differences in baseline charac-
teristics between the patients in the two groups regarding
age, lung function, proportion of current smokers, length of
illness before admission or proportion of patients who
received antibiotics and/or Prednisolone before admission.
There was a higher proportion of males in the p-AECOPD
group compared with the np-AECOPD group (67 versus
33 %, p\ 0.01), and a larger proportion of patients were
treated with antibiotics after admission in the p-AECOPD
group compared with those in the np-AECOPD group (48
versus 92 %, p\ 0.01), Table 1.
Data on the CD64, CRP and WBC values were complete
at admission in 98 patients, 31 (86 %) in the p-AECOPD
group versus 67 (87 %) in the np-AECOPD group. In the
p-AECOPD group, the median values of CD64, CRP and
WBC were statistically significantly higher than in the np-
AECOPD: 1.25 versus 0.60 (p\ 0.01), 81.5 versus 12.0
(p\ 0.01) and 12.75 versus 9.6 (p\ 0.01), respectively.
The diagnostic accuracy of the CD64, CRP and WBC in
differentiating between the np-AECOPD and p-AECOPD
was similar, with an area under the ROC curve of 0.69
(95 % CI 0.58–0.81) for CD64, 0.73 (95 % CI 0.62–0.84)
for CRP and 0.64 (95 % CI 0.52–0.76) for WBC (Fig. 1).
The differences were not statistically significant
(p = 0.42). In a logistic regression model with CRP and
WBC, CD64 did not reach statistical significance
(p = 0.48). There was a strong positive correlation
between CD64 and CRP, with rho = 0.64 (p\ 0.01), i.e.
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high levels of CD64 were associated with high levels of
CRP. Furthermore, there was no correlation between the
CD64 and WBC values.
There was a complete data set on the CD64 at admission
and 6, 24 and 48 h after admission in 25 patients in the
p-AECOPD group and 49 patients in the np-AECOPD
group (Table 2). At all test times, the CD64 values were
higher in the patients with p-AECOPD than the patients
with np-AECOPD, but only at admission did these differ-
ences reach statistical significance. In the p-AECOPD
group, the CD64 values in blood samples taken at admis-
sion and 6 h after admission were statistically significantly
higher than in samples taken 24 and 48 h after admission
(p\ 0.05). No such dependency on time was observed in
np-AECOPD patients.
A blood culture sample was taken in 26 patients with np-
AECOPD and in 17 patients with p-AECOPD, but bac-
teremia was not present in any of the samples.
At admission, sputum samples were taken in 51 patients
with np-AECOPD and in 19 patients with p-AECOPD.
Table 1 Demographic characteristics and disease status of the study population by groups
Characteristics Study population (n = 113) p value p-AECOPD versus
np-AECOPD
p-AECOPD (n = 36) np-AECOPD (n = 77)
Age 68.0 71.0 0.4
Median (IQR) (65.0, 76.0) (65.0, 76.0)
Sex male, n (%) 24 (67) 25 (33) 0.001
Current smokers, n (%) 9 (25.0) 31 (40.3) 0.1
FEV1, median (IQR) 0.79 (0.56,1.19) 0.74 (0.52,0.93) 0.4
FEV1%, median (IQR) 27 (20,41) 28 (22,43) 0.5
FVC, median (IQR) 1.92 (1.82, 2.43) 1.73 (1.73,2.10) 0.3
FVC %, median (IQR) 52 (50, 62) 55 (56, 65) 0.2
FEV1/FVC, median (IQR) 0.42 (0.39, 0.50) 0.43 (0.41, 0.42) 0.7
Length of illness before hospitalization, days (n),
median (IQR)
6 (3.0,7.8) 7 (1.5,12.0) 0.9
Treatment before admission, n (%)
Antibiotics 10 (28) 18 (23) 0.6
Oral steroid 12 (33) 26 (34) 1.0
Treatment after admission, n (%)
Antibiotics 33 (92) 37 (48) 0.001
Oral steroids 32 (89) 68 (88) 1.0
Regular medication, combination ICS with LABA 29 (81) 55 (71) 0.2
Blood parameters at admission, median (IQR)
WBC 12.8 (8.9,16.2) 9.6 (7.8,12.4) 0.001
CRP 81.5 (18.3,163.5) 12.0 (5.0,50.0) 0.001
CD64 1.25 (0.70,1.95) 0.60 (0.5,1.0) 0.002
AECOPD acute exacerbations of chronic obstructive lung disease, p-AECOPD AECOPD with pulmonary infiltrate on chest X-ray at admission,
np-AECOPD AECOPD without pulmonary infiltrate on chest X-ray at admission, IQR interquartile range, FEV1 forced expiratory volume (litres)
in one second, FEV1% FEV1 percent of predicted value, FVC forced vital capacity (litres), FVC% FVC percent of predicted value, FEV1/FVC
FEV1 expressed as a proportion of FVC, ICS inhaled corticosteroids, LABA long-acting beta-adrenoceptor agonist, WBC white blood cell, CRP
C-reactive protein, CD64 neutrophil CD expression
Fig. 1 Receiver operating characteristic (ROC) curves for CD64,
WBC and CRP measured in samples taken at admission. The curves
show how sensitivity (true positive fraction) varies with 1-specificity
(false positive fraction) when the diagnostic cut-off limit is varied
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Pathogens were found in 29 samples from the np-AECOPD
group and in 10 samples from the p-AECOPD group.
Individual CD64 values with corresponding findings in the
sputum samples are shown in Table 3. H. influenza
(n = 11), M. catarrhalis (n = 5), S. pneumonia (n = 6)
and S. aureus (n = 3) were the agents most commonly
found in the sputum samples. Mixed cultures, bacte-
rial ? bacterial (n = 5) and bacterial ? viral (n = 3) were
found exclusively in samples from patients with np-
AECOPD. There was a great variability in the CD64 values
between samples that were positive for the same pathogen.
Discussion
In the present study, we showed that the expression of
CD64 on neutrophils is higher in patients with p-AECOPD
than in patients with np-AECOPD, both at admission to the
hospital and during the following 48 h.
To the best of our knowledge, this is the first report on
the diagnostic accuracy of the CD64 in identifying those
with pneumonia among patients with AECOPD applied in
a real clinical setting in which acutely ill patients were
being examined. Two previous studies have covered some
aspects of the CD64 expression in patients with AECOPD.
In the study by Zhang and colleagues [30], the CD64
expression in patients with AECOPD and healthy subjects
was compared, and in the study by Mao and colleagues
[31] the CD64 expression in patients with AECOPD,
patients with stable COPD and healthy subject were com-
pared. The CD64 expression was higher in those with
AECOPD than in patients with stable COPD. There was no
difference in the CD64 expression between patients with
stable COPD and healthy subjects. However, none of these
studies evaluated the diagnostic accuracy of the CD64 to
distinguish between p-AECOPD and np-AECOPD. In the
present study, the elevated CD64 values in patients with
p-AECOPD declined between 6 and 24 h after admission.
However, it should be noted that 92 % of the patients in the
p-AECOPD group received antibiotics, and changes in
CD64 expression may be related to the antibiotic treatment
through restoration of the regulated immune response by
such treatments. This finding may indicate that measuring
the CD64 expression might be useful in monitoring the
effects of antibiotic therapy implying that CD64 could be
used as a prognostic marker. The kinetics of the CD64
expression found in this study is supported by the findings
of other researchers [23, 32].
The diagnostic accuracy of CD64 in differentiating
between p-AECOPD and np-AECOPD was about the same
as that of CRP. Furthermore, CD64 did not add to the
diagnostic accuracy of CRP and WBC counts when these
laboratory tests were combined to discriminate between
p-AECOPD and np-AECOPD. It must be considered that
these findings are partly due to some limitations of the
present study. First, the study population is rather small,
and therefore the confidence intervals of the ROC areas are
relatively wide. The differences between CD64, CRP and
WBC counts might have been statistically significant in a
larger population. Second, some patients included in the
study were treated with systemic steroids and/or antibiotics
before admission. If all patients were left untreated until
admission, the diagnostic accuracy might have been better
for all the laboratory tests. Third, the study was not
designed with regard to microbiological diagnostics. In a
small number of patients, blood culture samples were
requested by the physician in charge, but bacteremia was
not present in any of the samples. Advanced microbio-
logical analysis of sputum was not performed routinely.
Hence, we were not able to correlate the CD64 levels with
bacteriological or viral findings. Our data are consistent
with results from previous studies regarding the association
of H. influenzae, M. catarrhalis and S. pneumonia with
AECOPD [33–36]. An interesting question that ought to be
addressed in future studies is whether CD64 has the
potential as a useful biomarker in distinguishing between
an acute airway infection or colonization of the airways
with one or more bacteria.
Table 2 Median value of CD64 in blood samples taken at admission to the hospital, and 6, 24 and 48 h after admission, from patients with
(p-AECOPD) and without (np-AECOPD) pulmonary infiltrate
Time of sampling in hours
after admission
p-AECOPD (n = 25) np-AECOPD (n = 49) p value p-AECOPD
versus np-AECOPD
0 1.30 (0.60, 2.05)a 0.60 (0.50, 1.10) 0.05
6 1.20 (0.50, 2.20)a 0.70 (0.50, 1.12) 0.07
24 0.90 (0.50, 2.25) 0.70 (0.50, 1.30) 0.20
48 1.00 (0.57, 1.55) 0.70 (0.50, 1.00) 0.09
AECOPD acute exacerbations of chronic obstructive lung disease, p-AECOPD AECOPD with pulmonary infiltrate on chest X-ray at admission,
np-AECOPD AECOPD without pulmonary infiltrate on chest X-ray on admission
a Statistically significant higher values than measured in samples taken 24 and 48 h after admission. The numbers in parentheses are the
corresponding interquartile ranges
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The strength of the present study is the clinical validity
of the study population prospectively included when
admitted to hospital because of an AECOPD and the
clinically relevant diagnostic procedure of p-AECOPD by
chest X-rays without any knowledge of the value of CD64
or any other laboratory tests.
Table 3 The individual values
of neutrophil CD64 expression
and positive culture findings
Recognized agents Values of neutrophil CD64 expression
























b-haemolytic Streptococcus group B 1.0


















Proteus mirabilis ? Rhinovirus PCR positive 0.9c
Influenza A virus subtype H1N1 1.7c
Enterobacter cloacae 0.9c
Candida albicans 1.1 1.3c
Acinetobacter baumannii 0.5d
Gram-negative bacteria 2.2b
a Treated with antibiotics before admission
b Treated with steroids per os before admission
c Treated with both steroids and antibiotics
d CD64 results from samples 6h after admission
AECOPD acute exacerbations of chronic obstructive lung disease, p-AECOPD AECOPD with pulmonary
infiltrate on chest X-ray at admission, np-AECOPD AECOPD without pulmonary infiltrate on chest X-ray
at admission
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Conclusion
When used for diagnosing pneumonia in patients with an
acute exacerbations of COPD, CD64 had about the same
diagnostic accuracy as CRP, and CD64 did not seem to add
to the diagnostic accuracy of CRP and WBC counts.
Acknowledgments The authors would like to acknowledge the
personnel of the Emergency Department, Departments of Thoracic
Medicine, Clinical Chemistry and Medical Microbiology of the
Trondheim University Hospital for their assistance. The authors
would like to acknowledge Unimed Innovation AS, Trondheim
University Hospital Foundation and the Research Council of Norway
for partial support of this study.
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no financial
or non-financial conflicts of interests.
Research Involving Human Participants All procedures per-
formed in studies involving human participants were in accordance
with the ethical standards of the Regional Committee for Medical and
Health Research Ethics (REC) and with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Global Strategy for Diagnosis, Management, and Prevention of
COPD Updated January (2015) Global initiative for chronic
obstructive lung disease. http://www.goldcopd.org/. Accessed
July 2015
2. Perera WR, Hurst JR, Wilkinson TM et al (2007) Inflammatory
changes, recovery and recurrence at COPD exacerbation. Eur
Respir J 29(3):527–534. doi:10.1183/09031936.00092506
3. Hurst JR, Perera WR, Wilkinson TM et al (2006) Systemic and
upper and lower airway inflammation at exacerbation of chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
173(1):71–78. doi:10.1164/rccm.200505-704OC
4. Seemungal TA, Hurst JR, Wedzicha JA (2009) Exacerbation rate,
health status and mortality in COPD—a review of potential
interventions. Int J Chronic Obstr Pulm Dis 4:203–223
5. Wedzicha JA, Brill SE, Allinson JP et al (2013) Mechanisms and
impact of the frequent exacerbator phenotype in chronic
obstructive pulmonary disease. BMC Med 11:181. doi:10.1186/
1741-7015-11-181
6. Seemungal T, Harper-Owen R, Bhowmik A et al (2001) Respi-
ratory viruses, symptoms, and inflammatory markers in acute
exacerbations and stable chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 164(9):1618–1623. doi:10.1164/
ajrccm.164.9.2105011
7. Wedzicha JA (2004) Role of viruses in exacerbations of chronic
obstructive pulmonary disease. Proc Am Thorac Soc
1(2):115–120. doi:10.1513/pats.2306030
8. Papi A, Luppi F, Franco F et al (2006) Pathophysiology of
exacerbations of chronic obstructive pulmonary disease. Proc Am
Thorac Soc 3(3):245–251. doi:10.1513/pats.200512-125SF
9. Peacock JL, Anderson HR, Bremner SA et al (2011) Outdoor air
pollution and respiratory health in patients with COPD. Thorax
66(7):591–596. doi:10.1136/thx.2010.155358
10. Quint JK, Donaldson GC, Goldring JJ et al (2010) Serum IP-10 as
a biomarker of human rhinovirus infection at exacerbation of
COPD. Chest 137(4):812–822. doi:10.1378/chest.09-1541
11. Hurst JR, Donaldson GC, Perera WR et al (2006) Use of plasma
biomarkers at exacerbation of chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 174(8):867–874. doi:10.
1164/rccm.200604-506OC
12. Hoffmann JJ (2009) Neutrophil CD64: a diagnostic marker for
infection and sepsis. Clin Chem Lab Med 47(8):903–916. doi:10.
1515/cclm.2009.224
13. Bakke AC, Allen E, Purtzer MZ et al (2001) Neutrophil CD64
expression distinguishing acute inflammatory autoimmune dis-
ease from systemic infections. Clin Appl Immunol Rev
1(5):267–275
14. Davis BH, Olsen SH, Ahmad E et al (2006) Neutrophil CD64 is
an improved indicator of infection or sepsis in emergency
department patients. Arch Pathol Lab Med 130(5):654–661.
doi:10.1043/1543-2165(2006)130[654:nciaii]2.0.co;2
15. Livaditi O, Kotanidou A, Psarra A et al (2006) Neutrophil CD64
expression and serum IL-8: sensitive early markers of severity
and outcome in sepsis. Cytokine 36(5–6):283–290. doi:10.1016/j.
cyto.2007.02.007
16. Cardelli P, Ferraironi M, Amodeo R et al (2008) Evaluation of
neutrophil CD64 expression and procalcitonin as useful markers
in early diagnosis of sepsis. Int J Immunopathol Pharmacol
21(1):43–49
17. Farias MG, de Lucena NP, Dal Bo S et al (2014) Neutrophil
CD64 expression as an important diagnostic marker of infection
and sepsis in hospital patients. J Immunol Methods 414:65–68.
doi:10.1016/j.jim.2014.07.011
18. Gamez-Diaz LY, Enriquez LE, Matute JD et al (2011) Diagnostic
accuracy of HMGB-1, sTREM-1, and CD64 as markers of sepsis in
patients recently admitted to the emergency department. Acad
EmergMed 18(8):807–815. doi:10.1111/j.1553-2712.2011.01113.x
19. Hsu KH, Chan MC, Wang JM et al (2011) Comparison of
Fcgamma receptor expression on neutrophils with procalcitonin
for the diagnosis of sepsis in critically ill patients. Respirology
16(1):152–160. doi:10.1111/j.1440-1843.2010.01876.x
20. Doi T, Miyazaki T, Nishino J et al (2010) Neutrophil CD64
expression as a diagnostic marker for local infection and crystal-
induced arthritis. Mod Rheumatol 20(6):573–579. doi:10.1007/
s10165-010-0322-6
21. Matsui T, Ohsumi K, Ozawa N et al (2006) CD64 on neutrophils
is a sensitive and specific marker for detection of infection in
patients with rheumatoid arthritis. J Rheumatol 33(12):2416–
2424
22. Allen E, Bakke AC, Purtzer MZ et al (2002) Neutrophil CD64
expression: distinguishing acute inflammatory autoimmune dis-
ease from systemic infections. Ann Rheum Dis 61(6):522–525
23. FjaertoftG,HakanssonLD,PauksensKet al (2007)NeutrophilCD64
(FcgammaRI) expression is a specificmarker of bacterial infection: a
study on the kinetics and the impact of major surgery. Scand J Infect
Dis 39(6–7):525–535. doi:10.1080/00365540601113693
24. Rudensky B, Sirota G, Erlichman M et al (2008) Neutrophil
CD64 expression as a diagnostic marker of bacterial infection in
febrile children presenting to a hospital emergency department.
Pediatr Emerg Care 24(11):745–748. doi:10.1097/PEC.
0b013e31818c2679
25. Jalava-Karvinen P, Hohenthal U, Laitinen I et al (2009) Simul-
taneous quantitative analysis of Fc gamma RI (CD64) and CR1
Lung (2015) 193:717–724 723
123
(CD35) on neutrophils in distinguishing between bacterial
infections, viral infections, and inflammatory diseases. Clin
Immunol 133(3):314–323. doi:10.1016/j.clim.2009.08.003
26. Fjaertoft G, Pauksen K, Hakansson L et al (2005) Cell surface
expression of Fc gamma RI (CD64) on neutrophils and mono-
cytes in patients with influenza A, with and without complica-
tions. Scand J Infect Dis 37(11–12):882–889. doi:10.1080/
00365540500348929
27. Nuutila J (2010) The novel applications of the quantitative
analysis of neutrophil cell surface FcgammaRI (CD64) to the
diagnosis of infectious and inflammatory diseases. Curr Opin
Infect Dis 23(3):268–274. doi:10.1097/QCO.0b013e32833939b0
28. Cid J, Aguinaco R, Sanchez R et al (2010) Neutrophil CD64
expression as marker of bacterial infection: a systematic review
and meta-analysis. J Infect 60(5):313–319. doi:10.1016/j.jinf.
2010.02.013
29. Li S, Huang X, Chen Z, Zhong H et al (2013) Neutrophil CD64
expression as a biomarker in the early diagnosis of bacterial
infection: a meta-analysis. Int J Infect Dis 17(1):e12–e23. doi:10.
1016/j.ijid.2012.07.017
30. Zhang LX, Ye J, Chen YB et al (2013) The effect of CD33
expression on inflammatory response in chronic obstructive pul-
monary disease. Immunol Investig 42(8):701–710. doi:10.3109/
08820139.2013.806542
31. Mao W, Jiang Y, Ouyang L et al (2014) Early diagnostic values
of CD64 and CD11b indices of peripheral white blood cells for
acute exacerbation of chronic obstructive pulmonary disease in
older adults. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
30(11):1201–1204
32. Barth E, Fischer G, Schneider EM et al (2001) Differences in the
expression of CD64 and mCD14 on polymorphonuclear cells and
on monocytes in patients with septic shock. Cytokine
14(5):299–302. doi:10.1006/cyto.2001.0880
33. Rosell A, Monso E, Soler N et al (2005) Microbiologic deter-
minants of exacerbation in chronic obstructive pulmonary dis-
ease. Arch Intern Med 165(8):891–897. doi:10.1001/archinte.
165.8.891
34. Miravitlles M, Espinosa C, Fernandez-Laso E et al (1999)
Relationship between bacterial flora in sputum and functional
impairment in patients with acute exacerbations of COPD. Study
Group of Bacterial Infection in COPD. Chest 116(1):40–46
35. Patel IS, Seemungal TA, Wilks M et al (2002) Relationship
between bacterial colonisation and the frequency, character, and
severity of COPD exacerbations. Thorax 57(9):759–764
36. Barker BL, Haldar K, Patel H et al (2015) Association between
pathogens detected using quantitative polymerase chain reaction
with airway inflammation in COPD at stable state and exacer-
bations. Chest 147(1):46–55. doi:10.1378/chest.14-0764
724 Lung (2015) 193:717–724
123
